| Value | ₹350.0 Cr |
|---|---|
| Execution period | December 2027 |
| manufacturing capacity | 6000.0 MTPA |
NSE filing, NSE: IOLCP. Summary written from the filing by ALFA Finder's alert engine.
IOL Chemicals and Pharmaceuticals Ltd: key numbers
- Share price
- ₹180.62
- Market cap
- ₹5,302 Cr
- Revenue (annual)
- ₹2,319 Cr
- Net profit (annual)
- ₹137.6 Cr
- P/E (TTM)
- 31.5×Sector 46.1×
- Promoter holding
- 62.28%+0.00% QoQ
- FII holding
- 7.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from IOL Chemicals and Pharmaceuticals Ltd
All →IOL Chemicals and Pharmaceuticals Board Meeting Date
IOL Chemicals scheduled its board meeting for 30 Oct 2026 to consider unaudited Q1/H1 results. Trading window remains closed until 2 Nov 2026.
IOL Chemicals and Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulations.
IOL Chemicals and Pharmaceuticals Regulatory Approval
IOL Chemicals and Pharmaceuticals Limited received EU-REACH registration for its product 'Triacetin', enabling the company to export this product to countries in the European Union.
IOL Chemicals and Pharmaceuticals Other Announcement
IOL Chemicals and Pharmaceuticals Limited informed the Exchange about the dispatch of reminder letters to shareholders holding physical shares for updating their KYC details.
IOL Chemicals and Pharmaceuticals Earnings Call Transcript: Key Takeaways
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
- Call
- Guides 20% growth
IOL Chemicals and Pharmaceuticals Capacity Expansion: ₹495 Cr Investment
IOLCP announces three capacity expansions at Barnala: 6,000 MTPA Ibuprofen unit, CDMO formulation facility, and specialty chemicals tolling plant. Total investment ₹495 Crore funded via internal accruals.
- Value
- ₹495.0 Cr
- ibuprofen manufacturing capacity
- 6000 MTPA
Other capacity expansion announcements
All →Speciality Restaurants Capacity Expansion
Speciality Restaurants launched a new restaurant named WALTERS in Malad West, Mumbai, on October 28, 2026. The filing is a Reg 30 disclosure of a domestic restaurant launch with no monetary value stated.
- new restaurant outlets
- outlets
Goodluck India Capacity Expansion: ₹80 Cr Investment
Goodluck India's subsidiary Goodluck Defence and Aerospace approved adding Aerospace Components as a new line of business. The estimated investment is Rs 80 Crore, within a previously approved capital outlay.
- Value
- ₹80.00 Cr
Borosil Scientific Capacity Expansion: ₹70 Cr Investment
Borosil Scientific approved a Rs.70 Crore, 20 MT per day glass tubing furnace. Commercial production is expected by March 2028.
- Value
- ₹70.00 Cr
- Execution
- Commercial production expected by March 31, 2028
- borosilicate glass tubing production capacity
- 20.0 MT per day
Forbes Precision Tools and Machine Parts Capacity Expansion: ₹60 Cr Investment
Forbes Precision approved a Rs.60 Crore investment to add 10 lakh units annually within 1 to 1.5 years. Funding will combine internal accruals and debt.
- Value
- ₹60.00 Cr
- Execution
- 1 to 1.5 year
- production capacity
- 10.0 lakh units per annum
Diensten Tech Capacity Expansion
Diensten Tech's board approved incorporating a UAE subsidiary in IT consultancy, with the investment amount not yet fixed. Name, capital and incorporation date will be disclosed on completion.
- Execution
- Approximately 3 months from board approval, subject to regulatory approvals
Supreme Holdings & Hospitality (India) Capacity Expansion
Supreme Holdings approved a related-party joint development deal for a Panvel plot, pending shareholder approval. The project targets about 1 lakh sq ft saleable area.
- saleable area
- 100000.0 sq ft